Key clinical point: Use of amyloid PET may help to distinguish inclusion body myositis from polymyositis and diagnose the condition early.
Major finding: Median total standardized uptake value ratios for [18F]florbetapir were significantly higher for patients with inclusion body myositis (1.45; interquartile range, 1.28-2.05) than they were for those with polymyositis (1.01; IQR, 0.80-1.22; P = .005).
Study details: A clinical review of 10 patients with inclusion body myositis and 6 patients with polymyositis using amyloid PET imaging with [18F]florbetapir (Amyvid).
Disclosures: This study was supported by grants from the National Institute for Health Research Manchester Musculoskeletal Biomedical Research Centre, the Medical Research Council, and an award from the Centre for Imaging Sciences at the University of Manchester. The authors reported no conflicts of interest. Dr. Lloyd reported being a consultant for Acceleron and principal investigator for IBM clinical trials sponsored by Orphazyme and Regeneron.
Lilleker JB et al. Ann Rheum Dis. 2019 Feb 13. doi: 10.1136/annrheumdis-2018-214644.